Cargando…
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfai...
Autores principales: | Arenas, Enrique J., Martínez-Sabadell, Alex, Rius Ruiz, Irene, Román Alonso, Macarena, Escorihuela, Marta, Luque, Antonio, Fajardo, Carlos Alberto, Gros, Alena, Klein, Christian, Arribas, Joaquín |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902842/ https://www.ncbi.nlm.nih.gov/pubmed/33623012 http://dx.doi.org/10.1038/s41467-021-21445-4 |
Ejemplares similares
-
Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023) -
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
por: Ahmed, Nabil, et al.
Publicado: (2015) -
Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice
por: Martínez-Sabadell, Alex, et al.
Publicado: (2022) -
The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023) -
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)